Get the latest tech news
Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M
Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding.
“Our AI platform and expert teams enable us to identify and discover novel disease biology and match it with suitable small molecules,” Healx co-founder and CEO Tim Guilliams told TechCrunch. The problem, however, is that this is hugely time-consuming and has high failure rates, which is where Healx promises to help by analyzing millions of drug and disease data points in tandem to find hitherto undetected connections that could present new treatments using known compounds. Image Credits: HealxThe Phase 2 trials of Healx’s NF1 lead candidate, dubbed HLX-1502 (a tablet taken orally), are expected to start by the end of 2024, and will focus on young adults with NF1 and inoperable plexiform neurofibroma, a specific type of tumor associated with NF1.
Or read this on TechCrunch